Acta Scientific Otolaryngology (ASOL) (ISSN: 2582-5550)

Review Article Volume 3 Issue 8

Mucormycosis- A Post Covid Challenge in India

Amil Sharma1*, Sarvesha Bhondwe2, Rupali Balpande3, Arpit Sikri4, Sharmishtha Sharma5 and Nirmal Tawar6

1Senior Lecturer, Department of Conservative Dentistry and Endodontics, Maharana Pratap College of Dentistry and Research Centre, Gwalior, Madhya Pradesh, India

2Professor and Head, Department of Conservative Dentistry and Endodontics, Y C M M & R D F’s Dental College and Hospital, Ahmednagar, India

3Private practitioner Nagpur, Maharashtra, India

4Reader, Bhojia Dental College Baddi, Himachal Pradesh, India

5Private Practitioner, Gwalior, Madhya Pradesh, India

6Private Practitioner, Hoshangabad, Madhya Pradesh, India

*Corresponding Author: Amil Sharma, Senior Lecturer, Department of Conservative Dentistry and Endodontics, Maharana Pratap College of Dentistry and Research Centre, Gwalior, Madhya Pradesh, India.

Received: June 21, 2021; Published: July 14, 2021


In 2019, an unknown virus known as Covid-19 was discovered in Wuhan, China. The first case of Covid-19 was discovered in India on January 30, 2020. In March 2020 it was declared as a global pandemic by World Health Organization. In 2021 India faced the 2nd wave of Covid-19. Among the patients recovered from Covid19, few developed opportunistic infection with Black fungus also known as Mucormycosis. Diabetes Mellitus was found to be a risk factor in mucormycosis. The main aim of this article is to conduct a detailed review of mucormycosis infection.

Keywords: Mucormycosis; Covid 19; Steroids; Diabetes Mellitus


  1. Awadhesh Kumar Singh., et al. “Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India Diabetes and Metabolic Syndrome: Clinical Research and Reviews 1-29 (2021).
  2. Ajit Auluck. “Maxillary necrosis by mucormycosis. A case report and literature review”. Medicina Oral, Patologia Oral, Cirugia Bucal 12 (2007): E360-364.
  3. Syeda Neelam Afroze., et al. “MadalaMucormycosis in a Diabetic Patient: A Case Report with an Insight into Its Pathophysiology”. Contemporary Clinical Dentistry (2017): 662-666.
  4. Sandip Sarkar., et al. “COVID‑19 and orbital mucormycosis”. Indian Journal of Ophthalmology 4 (2021): 1002-1004.
  5. Mehta S. “Rhino-Orbital Mucormycosis Associated With COVID-19”. Cureus9 (2020): e10726.
  6. Ourania Nicolatou-Galitis., et al. “Mucormycosis presenting with dental pain and palatal ulcer in a patient with chronic myelomonocytic leukaemia: case report and literature review”. JMM Case Reports (2015): 1-8.
  7. JG Song., et al. “Invasive pulmonary aspergillosis histologically mimicking mucormycosis”. The Ewha Medical Journal2 (2016): 65-68.
  8. Aastha Maini., et al. “Sino-orbital mucormycosis in a COVID-19 patient: A case report”. International Journal of Surgery Case Reports 82 (2021): 105957.
  9. Prakash H and Chakrabarti A. “Epidemiology of Mucormycosis in India”. Microorganisms 9 (2021): 523.
  10. Amudhan A., et al. “Fungal Infection Emerging Into Oral Cavity: A Rare Case Report with Review of Literature Research Journal of Pharmaceutical, Biological and Chemical Sciences 5.6 (2014): 82-87.
  11. Arvind Babu Rajendra Santosh., et al. “Fungal Infections of Oral Cavity: Diagnosis, Management, and Association with COVID-19 SN Comprehensive”. Clinical Medicine 3 (2021): 1373-1384.
  12. Kumar JA., et al. “Mucormycosis in maxilla: Rehabilitation of facial defects using interim removable prostheses: A clinical case report”. Journal of Pharmacy and Bioallied Sciences 5 (2013): S163-165.
  13. Sridhar Gontu Reddy., et al. “Oral mucormycosis: Need for early diagnosis!!” Journal of Dr. NTR University of Health Sciences2 (2014): 145-147.
  14. Robert Branscomb. “An Overview of Mucormycosis ; laboratory medicine 6.33 (2002): 453-455.
  15. Song G., et al. “Fungal co-infections associated with global COVID-19 pandemic: a clinical and diagnostic perspective from China”. Mycopathologia 185 (2020): 599-606.
  16. Kubin CJ., et al. “Characterization of Bacterial and Fungal Infections in Hospitalized Patients with COVID-19 and Factors Associated with Healthcare-associated Infections”. Open Forum Infectious Diseases (2021): ofab201.
  17. Chander J., et al. “Mucormycosis: battle with the deadly enemy over a five-year period in India”. Journal of Fungi2 (2018): 46.
  18. Prakash H and Chakrabarti A. “Global epidemiology of mucormycosis”. Journal of Fungi 5 (2019): 26.
  19. Baker RD. “Mucormycosis-a new disease?” The Journal of the American Medical Association 163 (1957): 805-808.


Citation: Amil Sharma., et al. “Mucormycosis- A Post Covid Challenge in India" Acta Scientific Otolaryngology 3.8 (2021): 65-68.


Copyright: © 2021 Amil Sharma., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Acceptance rate34%
Acceptance to publication20-30 days
Impact Factor0.871

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is May 30, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US